An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

Regarding diabetic retinopathy’s prevalence, , there are 40 million Americans who have diabetes, and about 60% of them of them will go on to get diabetic eye disease.

An automated grading system for detection of vision-threatening referable diabetic retinopathy on the basis of color fundus photographs. Diabetes Care. 2018;41 (12):2509-2516. doi: 10.2337/dc18-0147.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.